Ionizable compounds and compositions and uses thereof
This invention includes ionizable compounds, and compositions and methods of use thereof. The ionizable compounds can be used for making nanoparticle compositions for use in biopharmaceuticals and therapeutics. More particularly, this invention relates to compounds, compositions and methods for providing nanoparticles to encapsulate active agents, such as nucleic acid agents, and to deliver and distribute the active agents to cells, tissues, organs, and subjects.
1. A compound comprising the structure shown in Formula I
wherein R 1 and R 2 are
R 1 =CH 2 (CH 2 ) n OC(═O)R 4
R 2 =CH 2 (CH 2 ) m OC(═O)R 5
wherein n and m are each independently from 1 to 2; and R 4 and R 5 are independently for each occurrence a C(12-20) alkyl group, or a C(12-20) alkenyl group;
wherein R 3 is selected from
wherein
each R 6 is independently selected from H, alkyl, hydroxyl, hydroxyalkyl, alkoxy, alkoxyalkoxy, and aminoalkyl;
each R 7 is independently selected from H, alkyl, hydroxyalkyl, and aminoalkyl;
Q is O or NR 7 .
2. The compound of claim 1 , wherein alkyl is C(1-6)alkyl, hydroxyalkyl, is hydroxyl[C(1-6)alkyl], and aminoalkyl is amino[C(1-6)alkyl].
3. The compound of claim 1 , R 4 and R 5 are independently for each occurrence a C(14-18) alkyl group, or a C(14-18) alkenyl group.
4. The compound of claim 1 , wherein Q is O.
5. The compound of claim 1 , having a structure selected from
6. A composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
7. The composition of claim 6 , wherein the composition comprises nanoparticles.
8. A pharmaceutical composition comprising a compound of claim 1 , an active agent, and a pharmaceutically acceptable carrier.
9. The composition of claim 8 , wherein the compound is from 15 mol % to 40 mol % of the lipids of the composition.
10. The composition of claim 8 , wherein the composition comprises nanoparticles.
11. The composition of claim 8 , wherein the active agent is one or more RNAi molecules.
12. The composition of claim 8 , wherein the active agent is one or more RNAi molecules selected from small interfering RNAs (siRNA), double stranded RNAs (dsRNA) that are Dicer substrates, microRNAs (miRNA), short hairpin RNAs (shRNA), DNA-directed RNAs (ddRNA), Piwi-interacting RNAs (piRNA), repeat associated siRNAs (rasiRNA), and modified forms thereof.
13. A composition for use in distributing an active agent for treating a condition or disease in a subject, the composition comprising a compound of claim 1 , a structural lipid, a stabilizer lipid, and a lipid for reducing immunogenicity of the composition.
14. The composition of claim 13 , wherein the active agent is one or more RNAi molecules and the composition comprises nanoparticles that encapsulate the RNAi molecules.
15. The composition of claim 14 , wherein the active agent is one or more RNAi molecules selected from small interfering RNAs (siRNA), double stranded RNAs (dsRNA) that are Dicer substrates, microRNAs (miRNA), short hairpin RNAs (shRNA), DNA-directed RNAs (ddRNA), Piwi-interacting RNAs (piRNA), repeat associated siRNAs (rasiRNA), and any modified forms thereof.
16. A method for ameliorating or treating a disease or condition in a subject in need comprising administering to the subject a composition of claim 8 .